Genelux is a biotechnology business based in the US. Genelux shares (GNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.55 – an increase of 8.05% over the previous week. Genelux employs 24 staff and has a trailing 12-month revenue of around $8,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.55 |
|---|---|
| 52-week range | $1.60 - $16.60 |
| 50-day moving average | $2.65 |
| 200-day moving average | $3.59 |
| Wall St. target price | $18.40 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.94 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.46 from 2024-11-21
| 1 week (2024-11-15) | 4.24% |
|---|---|
| 1 month (2024-10-24) | -2.38% |
| 3 months (2024-08-23) | 8.85% |
| 6 months (2024-05-23) | -46.52% |
| 1 year (2023-11-22) | -78.02% |
|---|---|
| 2 years (2022-11-20) | N/A |
| 3 years (2021-11-20) | N/A |
| 5 years (2019-11-20) | N/A |
| Revenue TTM | $8,000 |
|---|---|
| Gross profit TTM | $11.1 million |
| Return on assets TTM | -44.61% |
| Return on equity TTM | -88.57% |
| Profit margin | 0% |
| Book value | $0.74 |
| Market Capitalization | $86 million |
TTM: trailing 12 months
We're not expecting Genelux to pay a dividend over the next 12 months.
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California. .
Steps to owning and managing CRM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ORCL, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLTR, with 24-hour and historical pricing before you buy.
Steps to owning and managing NVDA, with 24-hour and historical pricing before you buy.
Steps to owning and managing INTC, with 24-hour and historical pricing before you buy.
Steps to owning and managing MSFT, with 24-hour and historical pricing before you buy.
Steps to owning and managing META, with 24-hour and historical pricing before you buy.
Steps to owning and managing GOOGL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMZN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AAPL, with 24-hour and historical pricing before you buy.